ICN's Failure To Disclose Ribavirin "Not Approvable" Letter Prompts SEC Suit

ICN Pharmaceuticals characterized FDA's November 1994 "not approvable" letter for ribavirin monotherapy as "typical regulatory correspondence" in communications with investors, the Securities and Exchange Commission charged in an Aug. 11 complaint filed in Los Angeles federal court.